Amgen (AMGN) Goodwill & Intangibles (2009 - 2026)
Amgen's quarterly Goodwill & Intangibles came in at $40.1 billion in Q1 2026, up 70.84% year-on-year from $23.4 billion in Q1 2025, and down 2.2% quarter-over-quarter from $41.0 billion in Q4 2025.
Amgen has reported Goodwill & Intangibles for 18 years, with the latest figure at $40.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles rose 70.84% year-over-year to $40.1 billion; the trailing twelve-month figure through Mar 2026 stood at $40.1 billion (up 70.84% YoY), and the FY2025 full-year result was $41.0 billion, down 11.61% from the prior year.
- Goodwill & Intangibles for Q1 2026 stood at $40.1 billion, down from $41.0 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $51.3 billion in Q4 2023, with the low at $19.0 billion in Q2 2025.
- Average Goodwill & Intangibles over 5 years is $36.3 billion, with a median of $31.6 billion recorded in 2022.
- Year-over-year, Goodwill & Intangibles sank 61.01% in 2025 and soared 70.84% in 2026.
- Tracing AMGN's Goodwill & Intangibles over 5 years: stood at $31.6 billion in 2022, then jumped by 62.2% to $51.3 billion in 2023, then decreased by 9.62% to $46.3 billion in 2024, then decreased by 11.61% to $41.0 billion in 2025, then slipped by 2.2% to $40.1 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $40.1 billion (Q1 2026), $41.0 billion (Q4 2025), and $41.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.05 Bn |
| Dec 31, 2025 | 40.96 Bn |
| Sep 30, 2025 | 41.82 Bn |
| Jun 30, 2025 | 19.02 Bn |
| Mar 31, 2025 | 23.45 Bn |
| Dec 31, 2024 | 46.34 Bn |
| Sep 30, 2024 | 47.58 Bn |
| Jun 30, 2024 | 48.79 Bn |
| Mar 31, 2024 | 49.94 Bn |
| Dec 31, 2023 | 51.27 Bn |
| Sep 30, 2023 | 28.66 Bn |
| Jun 30, 2023 | 30.16 Bn |
| Mar 31, 2023 | 30.92 Bn |
| Dec 31, 2022 | 31.61 Bn |
| Sep 30, 2022 | 28.11 Bn |
| Jun 30, 2022 | 28.79 Bn |
| Mar 31, 2022 | 29.46 Bn |
| Dec 31, 2021 | 30.07 Bn |
| Sep 30, 2021 | 29.32 Bn |
| Jun 30, 2021 | 29.98 Bn |
| Mar 31, 2021 | 30.62 Bn |
| Dec 31, 2020 | 31.28 Bn |
| Sep 30, 2020 | 31.93 Bn |
| Jun 30, 2020 | 32.63 Bn |
| Mar 31, 2020 | 33.34 Bn |
| Dec 31, 2019 | 34.12 Bn |
| Sep 30, 2019 | 21.41 Bn |
| Jun 30, 2019 | 21.50 Bn |
| Mar 31, 2019 | 21.82 Bn |
| Dec 31, 2018 | 22.14 Bn |
| Sep 30, 2018 | 22.47 Bn |
| Jun 30, 2018 | 23.17 Bn |
| Mar 31, 2018 | 8.79 Bn |
| Dec 31, 2017 | 23.37 Bn |
| Sep 30, 2017 | 23.65 Bn |
| Jun 30, 2017 | 24.33 Bn |
| Mar 31, 2017 | 24.68 Bn |
| Dec 31, 2016 | 25.04 Bn |
| Sep 30, 2016 | 25.49 Bn |
| Jun 30, 2016 | 25.87 Bn |
| Mar 31, 2016 | 26.25 Bn |
| Dec 31, 2015 | 26.39 Bn |
| Sep 30, 2015 | 26.29 Bn |
| Jun 30, 2015 | 26.71 Bn |
| Mar 31, 2015 | 26.99 Bn |
| Dec 31, 2014 | 27.48 Bn |
| Sep 30, 2014 | 27.92 Bn |
| Jun 30, 2014 | 28.34 Bn |
| Mar 31, 2014 | 28.40 Bn |
| Dec 31, 2013 | 28.23 Bn |
| Sep 30, 2013 | 16.25 Bn |
| Jun 30, 2013 | 16.35 Bn |
| Mar 31, 2013 | 16.50 Bn |
| Dec 31, 2012 | 16.63 Bn |
| Sep 30, 2012 | 16.27 Bn |
| Jun 30, 2012 | 12.43 Bn |
| Mar 31, 2012 | 12.12 Bn |
| Dec 31, 2011 | 14.33 Bn |
| Dec 31, 2010 | 16.72 Bn |
| Mar 31, 2010 | 13.80 Bn |
| Dec 31, 2009 | 13.90 Bn |
| Sep 30, 2009 | 14.01 Bn |
| Jun 30, 2009 | 14.12 Bn |